Watson recalls fentanyl patches in US
This article was originally published in Scrip
Executive Summary
Watson Pharmaceuticalsis recalling one lot of fentanyl transdermal system patches in the US because of the potential for leakage. The 75μg/hr patches were shipped between January 30th and March 19th. Patches leaking fentanyl gel have been detected, potentially directly exposing patients and caregivers to the active ingredient. No injuries have been reported, but exposure to fentanyl gel may lead to respiratory depression, overdose and death. Leaks have proved to be a problem for several companies marketing fentanyl patches. Earlier this year Actavis recalled all fentanyl patches sold in the US owing to a possible fold-over defect that could cause leakage. Johnson & Johnson recalled all lots of 25μg/hour Duragesic patches and 25μg/hour fentanyl patches sold by Novartis's Sandoz unit because the products may have a cut along one side, which could result in leakage. Recalls also were initiated by J&J and Ranbaxy Laboratories in Canada.
You may also be interested in...
Rare Diseases: CBER Looks To ‘Lean Into’ Accelerated Approval, Align More With CDER
US FDA biologics center officials spoke about their efforts to increase collaboration and harmonization with the drugs center, and to internally involve more review disciplines in evaluating biomarker evidence, during a Reagan-Udall Foundation meeting that weighed potential use of accelerated approval for neuronopathic mucopolysaccharidoses disorders.
RWE: Non-Interventional Studies Must Be Able To Distinguish A True Treatment Effect, US FDA Says
Agency describes a host of issues sponsors should consider and address before pursuing observational or case-control studies to support regulatory decision-making on drug efficacy or safety; new draft guidance was issued under the FDA’s Real-World Evidence program.
Eye On ODAC: Former Members, FDA’s Pazdur Talk Pre-Meeting Mindsets, Impact Of Sponsor’s Experts
Oncologic Drugs Advisory Committee reps and the Oncology Center of Excellence director go behind the scenes to discuss FDA interactions with panelists, how opinions can change during a meeting, and why the voting question is important.